Compare
Abbott Laboratories vs Edwards Lifesciences (ABT vs EW)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Abbott Laboratories (ABT) returned -11.7% and Edwards Lifesciences (EW) +23.3%; so far this year the figures are -12.3% and +19.8%.
Abbott Laboratories is the larger company by market value, about 3.2 times the size of Edwards Lifesciences.
On trailing earnings, ABT trades at 40.9 times and EW at 57.7 times.
Revenue grew +10.0% at ABT and +13.4% at EW over the last year.
ABT yields 2.29%. EW pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABT | EW | |
|---|---|---|
| Price | $109.93 | $102.14 |
| 1-day | -3.23% | +1.31% |
| YTD | -12.26% | +19.81% |
| 1 year | -11.73% | +23.30% |
| 3 years | +15.70% | +60.02% |
| Market cap | $190.4B | $58.7B |
| P/E | 40.9 | 57.7 |
| P/S | 3.95 | 8.80 |
| P/B | 3.73 | 5.41 |
| Revenue growth | +10.00% | +13.40% |
| EPS growth | -66.20% | -23.70% |
| Gross margin % | 56.9 | 78.0 |
| Net margin % | 9.7 | 15.3 |
| ROE % | 9.2 | 9.4 |
| Debt / equity | 0.61 | 0.06 |
| FCF yield % | 3.5 | 2.4 |
| Dividend yield % | 2.29 | — |
| Beta | 0.06 | 0.52 |
| RSI (14) | 58.5 | 76.8 |
| Technical rating |